Výsledky vyhledávání - "Jennifer D Wu"

Akademický článek

The Human Soluble NKG2D Ligand Differentially Impacts Tumorigenicity and Progression in Temporal and Model-Dependent Modes

Autor: Anthony V. Serritella, Pablo Saenz-Lopez Larrocha, Payal Dhar, Sizhe Liu, Milan M. Medd, Shengxian Jia, Qi Cao, Jennifer D. Wu

Publikováno v: Biomedicines, Vol 12, Iss 1, p 196 (2024)

NKG2D is an activating receptor expressed by all human NK cells and CD8 T cells. Harnessing the NKG2D/NKG2D ligand axis has emerged as a viable avenue for cancer immunotherapy. However, there is a long-standing controversy over whether soluble NKG2D

Externí odkaz: https://doaj.org/article/c9111402da72415097efdb40a0bfedd3

Zobrazit plný text záznamu

Akademický článek

Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

Autor: Fahmin Basher, Payal Dhar, Xin Wang, Derek A. Wainwright, Bin Zhang, Jeffrey Sosman, Zhe Ji, Jennifer D. Wu

Publikováno v: Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-16 (2020)

Abstract Background Melanoma patients who have detectable serum soluble NKG2D ligands either at the baseline or post-treatment of PD1/PDL1 blockade exhibit poor overall survival. Among families of soluble human NKG2D ligands, the soluble human MHC I

Externí odkaz: https://doaj.org/article/adb45e608f324f5f9ccd09e0e52979ea

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy

Autor: Jinyu Zhang, Pablo Saenz-lopez Larrocha, Bin Zhang, Derek Wainwright, Payal Dhar, Jennifer D. Wu

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)

Abstract Background Insufficient co-stimulation accounts for a great deal of the suboptimal activation of cytotoxic CD8 T cells (CTLs) and presumably unsatisfactory clinical expectation of PD1/PD-L1 therapy. Tumor-derived soluble NKG2D ligands are as

Externí odkaz: https://doaj.org/article/87a84d4e39904cee95a00e1d5ff9564f

Zobrazit plný text záznamu

Akademický článek

Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies

Autor: Lijie Zhai, April Bell, Erik Ladomersky, Kristen L. Lauing, Lakshmi Bollu, Jeffrey A. Sosman, Bin Zhang, Jennifer D. Wu, Stephen D. Miller, Joshua J. Meeks, Rimas V. Lukas, Eugene Wyatt, Lynn Doglio, Gary E. Schiltz, Robert H. McCusker, Derek A. Wainwright

Publikováno v: Frontiers in Immunology, Vol 11 (2020)

Indoleamine 2, 3-dioxygenase 1 (IDO; IDO1; INDO) is a rate-limiting enzyme that metabolizes the essential amino acid, tryptophan, into downstream kynurenines. Canonically, the metabolic depletion of tryptophan and/or the accumulation of kynurenine is

Externí odkaz: https://doaj.org/article/739cbe66148b4c3487d236e84486ab82

Zobrazit plný text záznamu

Akademický článek

Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017)

Autor: Lijie Zhai, Erik Ladomersky, Kristen L. Lauing, Meijing Wu, Denise M. Scholtens, Rohan Savoor, Bin Zhang, Jennifer D. Wu, Craig Horbinski, Rimas V. Lukas, David C. Binder, Derek A. Wainwright

Publikováno v: OncoImmunology, Vol 8, Iss 3 (2019)

Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al. (2017) with respect to IDO1 among preclinical a

Externí odkaz: https://doaj.org/article/4f3c72e704db4a8ca010fd1b67d431de

Zobrazit plný text záznamu

Akademický článek

The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma

Autor: Erik Ladomersky, Denise M. Scholtens, Masha Kocherginsky, Elizabeth A. Hibler, Elizabeth T. Bartom, Sebastian Otto-Meyer, Lijie Zhai, Kristen L. Lauing, Jaehyuk Choi, Jeffrey A. Sosman, Jennifer D. Wu, Bin Zhang, Rimas V. Lukas, Derek A. Wainwright

Publikováno v: Frontiers in Pharmacology, Vol 10 (2019)

Background: Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and is associated with a median overall survival (mOS) of 16–21 months. Our previous work found a negative association between advanced aging and the survival benef

Externí odkaz: https://doaj.org/article/745b21c92aef40bba365cd55223a2191

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání